Dr. Reddy's Laboratories Limited DRREDDY NIFTY50NSEAIPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.drreddys.com

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Market & Price

Market Cap

₹1.09 L Cr

Current Price

₹1,303.50

High / Low (52W)

₹1,354.60 / ₹1,157.20

Beta

0.29

Valuation

Stock P/E

25.90

Industry PE

37.60

Forward P/E

20.21

PEG Ratio

3.79

Book Value

₹452.27

Price to Book

2.88

P/S

3.23

EV/EBITDA

15.31

Dividend Yield

0.61%

Profitability & Returns

ROCE

14.00%

ROE

11.83%

ROA

5.82%

Profit Margin

12.76%

Op Margin

5.20%

EPS (Latest Qtr)

₹2.65

EPS (TTM)

₹50.32

Balance Sheet & Liquidity

Debt/Equity

0.20

Quick Ratio

1.13

Current Ratio

1.80

Debt

₹7,734.10 Cr

Total Assets

₹57,934.60 Cr

Current Assets

₹30,197.50 Cr

Working Capital

₹13,440.90 Cr

Ownership

Promoter Holding

29.77%

Chg in Prom Hold

FII / Inst Holding

53.58%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

₹1.08 L Cr

Total Revenue (TTM)

₹33,593.30 Cr

EBITDA

₹7,050.80 Cr

Free Cash Flow

₹174.11 Cr

Operating Cash Flow

₹5,675.50 Cr

Shares Outstanding

₹83.26 Cr

Gross Margin

52.77%

Payout Ratio

15.89%

Growth (CAGR)

Revenue 5Y

10.96%

Profit 5Y

-2.35%

Revenue (YoY)

-11.60%

Earnings (YoY)

-86.20%

PROS

Compounding revenue at 11.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -2.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
7	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
8	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	965.10	65.34	₹93,927.75 Cr	0.16%	12.70%	14.33%	23.10%	9.34%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	8,506.00 Cr	8,545.20 Cr	8,805.10 Cr	8,726.80 Cr	7,516.20 Cr
Cost of Revenue	-	2,850.00 Cr	3,682.50 Cr	3,991.10 Cr	4,046.20 Cr	3,212.70 Cr
Gross Profit	-	5,656.00 Cr	4,862.70 Cr	4,814.00 Cr	4,680.60 Cr	4,303.50 Cr
Operating Expenses	-	4,036.00 Cr	3,178.50 Cr	3,027.30 Cr	3,247.60 Cr	4,220.60 Cr
Operating Income	-	1,620.00 Cr	1,684.20 Cr	1,786.70 Cr	1,433.00 Cr	82.90 Cr
EBITDA	-	2,525.50 Cr	2,464.20 Cr	2,430.80 Cr	2,158.60 Cr	862.50 Cr
Interest Expense	-	65.60 Cr	83.00 Cr	90.70 Cr	94.40 Cr	105.70 Cr
Pretax Income	-	2,005.20 Cr	1,904.70 Cr	1,835.00 Cr	1,542.90 Cr	199.70 Cr
Tax Provision	-	418.50 Cr	495.10 Cr	408.20 Cr	353.30 Cr	-21.60 Cr
Net Income	-	1,593.30 Cr	1,417.80 Cr	1,437.20 Cr	1,209.80 Cr	220.90 Cr
Diluted EPS	16.94	19.10	17.02	-	14.52	2.65

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	24,587.90 Cr	27,916.40 Cr	32,553.50 Cr	33,593.30 Cr
Cost of Revenue	-	10,653.60 Cr	11,555.70 Cr	9,979.90 Cr	12,239.20 Cr
Gross Profit	-	13,934.30 Cr	16,360.70 Cr	22,573.60 Cr	21,354.10 Cr
Operating Expenses	-	8,028.90 Cr	9,829.90 Cr	15,560.90 Cr	16,607.60 Cr
Operating Income	-	5,905.40 Cr	6,530.80 Cr	7,012.70 Cr	4,746.50 Cr
EBITDA	-	7,443.10 Cr	8,842.20 Cr	9,666.10 Cr	7,825.30 Cr
Interest Expense	-	142.80 Cr	171.10 Cr	282.90 Cr	373.80 Cr
Pretax Income	-	6,036.70 Cr	7,187.00 Cr	7,679.50 Cr	5,392.70 Cr
Tax Provision	-	1,530.00 Cr	1,618.60 Cr	1,954.30 Cr	1,235.10 Cr
Net Income	-	4,506.70 Cr	5,568.40 Cr	5,655.10 Cr	4,196.00 Cr
Diluted EPS	28.34	54.17	66.92	67.79	-

Compounded Sales Growth

5 Years:	10.96%
1 Year:	-11.60%

Compounded Profit Growth

5 Years:	-2.35%
1 Year:	-86.20%

Stock Price Performance

1 Year:	+5.09%
6 Months:	+6.30%
3 Months:	-0.30%
1 Month:	-1.98%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	32,185.40 Cr	38,751.80 Cr	49,298.90 Cr	57,934.60 Cr
Current Assets	-	20,425.30 Cr	24,804.90 Cr	25,011.20 Cr	30,197.50 Cr
Cash & Equivalents	-	577.90 Cr	710.70 Cr	1,465.40 Cr	1,536.80 Cr
Inventory	-	4,867.00 Cr	6,355.20 Cr	7,108.50 Cr	7,653.10 Cr
Receivables	-	7,248.50 Cr	8,029.80 Cr	9,042.00 Cr	10,121.90 Cr
Total Liabilities	-	9,086.30 Cr	10,696.80 Cr	15,582.30 Cr	19,888.90 Cr
Current Liabilities	-	8,584.50 Cr	9,603.90 Cr	13,039.20 Cr	16,756.60 Cr
Long Term Debt	380.00 Cr	-	380.00 Cr	380.00 Cr	1,220.30 Cr
Total Debt	-	1,347.20 Cr	2,002.00 Cr	4,676.60 Cr	7,734.10 Cr
Total Equity	-	23,099.10 Cr	28,055.00 Cr	33,338.80 Cr	37,706.30 Cr
Shares Outstanding	-	83.26 Cr	83.41 Cr	83.45 Cr	83.47 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	5,887.50 Cr	4,543.30 Cr	4,642.80 Cr	5,673.70 Cr
Investing Cash Flow	-	-4,137.30 Cr	-4,028.30 Cr	-5,807.70 Cr	-6,549.30 Cr
Financing Cash Flow	-	-2,686.10 Cr	-376.30 Cr	1,891.10 Cr	829.00 Cr
Capital Expenditure	-	-1,886.60 Cr	-2,743.50 Cr	-3,439.80 Cr	-3,840.50 Cr
Free Cash Flow	-	4,000.90 Cr	1,799.80 Cr	1,203.00 Cr	1,833.20 Cr
Net Change in Cash	-	-935.90 Cr	138.70 Cr	726.20 Cr	-46.60 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	56.7%	58.6%	69.3%	63.6%
Operating Margin %	-	24.0%	23.4%	21.5%	14.1%
Net Margin %	-	18.3%	19.9%	17.4%	12.5%
ROE %	-	19.5%	19.8%	17.0%	11.1%
ROCE %	-	25.0%	22.4%	19.3%	11.5%

Shareholding Pattern

Insiders

29.77%

Institutions

53.58%

Public Float

76.29%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DRREDDY

No recent headlines available.

DRREDDY · Healthcare